Verrica Pharmaceuticals
VRCA
49 hedge funds and large institutions have $29.9M invested in Verrica Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 15 increasing their positions, 15 reducing their positions, and 14 closing their positions.
38% more capital invested
Capital invested by funds: $21.8M → $29.9M (+$8.16M)
0% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 15
1.62% less ownership
Funds ownership: 4.12% → 2.49% (-1.6%)
14% less funds holding
Funds holding: 57 → 49 (-8)
37% less call options, than puts
Call options by funds: $86K | Put options by funds: $137K
57% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$625K |
| 2 |
BlackRock
New York
|
+$232K |
| 3 |
MML Investors Services
Springfield,
Massachusetts
|
+$158K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$109K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$99.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$1.03M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$919K |
| 3 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$864K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$556K |
| 5 |
Millennium Management
New York
|
-$204K |
VRCA Hedge Fund Activity: Q3 2022 in Review
49 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Verrica Pharmaceuticals (VRCA) for Q3 2022, worth a combined $29.9M — up 38% from $21.8M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of VRCA and 6 opened new positions — a net loss of 8 holders — while 15 trimmed existing stakes and 15 added.
The largest buyer was Renaissance Technologies, adding an estimated $625K. The largest seller was Royal Bank of Canada, cutting an estimated $1.03M.
- 49 institutional investors held Verrica Pharmaceuticals (VRCA) as of Q3 2022, down from 57 in Q2 2022.
- Funds reported $29.9M of Verrica Pharmaceuticals stock for Q3 2022, up 38% quarter-over-quarter.
- 6 funds opened new Verrica Pharmaceuticals positions in Q3 2022 and 14 closed out, a net change of -8 holders.
- The largest Verrica Pharmaceuticals buyer in Q3 2022 was Renaissance Technologies, an estimated $625K added.
- The largest Verrica Pharmaceuticals seller in Q3 2022 was Royal Bank of Canada, an estimated $1.03M sold.
Based on aggregated 13F filings for Q3 2022.